Clinical trials: in The Gambia
Healthy
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies.
- Trial name
- NCT07160244
- Testing
- Multivalent Group B streptococcus vaccine, Infanrix hexa, Prevenar 20
- Where
- 219 sites in United States, Argentina and 13 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Pfizer
RSV Infection
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the…
- Trial name
- NCT06866405
- Testing
- RSVpreF
- Where
- 97 sites in United States, Argentina and 2 more
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningoccocal Disease
Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
- Trial name
- PERS-ACYWX-03 (NCT07379151)
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Salmonella Infections
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid…
- Trial name
- NCT07286370
- Testing
- Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV
- Where
- The Gambia
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria Infection
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and…
- Trial name
- NCT05974267
- Testing
- M5717 60 mg, Pyronaridine, Atovaquone-Proguanil
- Where
- 4 sites in Burkina Faso, Kenya and 2 more
- Volunteers
- 192 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Respiratory Tract Infection
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in…
- Trial name
- NCT04424316
- Testing
- RSVpreF
- Where
- 464 sites in United States, Argentina and 16 more
- Volunteers
- 14,727 people, healthy volunteers welcome
- Sponsor
- Pfizer
Yellow Fever
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
The study is designed as a Phase III, double-blind, multi-center, randomized, active-controlled study in which four groups of participants (n=554 per group) will receive either one of three different manufacturing lots of SII-YFV…
- Trial name
- NCT05447377
- Testing
- SII Yellow Fever Vaccine, STAMARIL®
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 2,216 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Measles, Rubella
Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial
This is a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial. Age de-escalation will be based on a review of the safety data from the preceding cohort (adults for toddlers…
- Conditions
- Measles, Rubella, Vaccination, Healthy
- Trial name
- NCT04394689
- Testing
- Measles Rubella Vaccine (MRV-SC), MRV-MNP, PLA-MNP
- Where
- The Gambia
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Micron Biomedical, Inc
Meningococcal Meningitis
Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)
This observer-blind, randomized, active controlled trial will be conducted among 2-29 year olds in two sites (Mali and The Gambia).
- Trial name
- NCT03964012
- Testing
- NmCV-5, Menactra
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria,Falciparum
Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections
This study will assess the efficacy of Pyramax administered for three-day, two-day or one day, in clearing a P. falciparum infection in asymptomatic carriers. .
- Trial name
- NCT03814616
- Testing
- Pyronaridine tetraphosphate 180mg:artesunate 60mg
- Where
- 2 sites in The Gambia, Zambia
- Volunteers
- 300 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Tuberculosis
Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants
This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme of Immunisation vaccines…
- Trial name
- NCT01098474
- Testing
- GSK's investigational vaccine 692342, Tritanrix™ HB+Hib, Prevnar™
- Where
- The Gambia
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants
This study will assess the impact on nasopharyngeal carriage, safety and immunogenicity of GSK Biologicals' pneumococcal vaccine 2189242A given as a 3-dose vaccination course and co-administered with other routine paediatric…
- Trial name
- NCT01262872
- Testing
- Pneumococcal vaccine GSK 2189242A (LD formulation 1), Pneumococcal vaccine GSK 2189242A (HD formulation 2), Synflorix™
- Where
- The Gambia
- Volunteers
- 1,320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria
Drug resistance to a range of antimalarial treatments has become widespread in Africa, South East Asia and South America. Because the rapid spread of drug resistance threatens a public health disaster in these areas of the world…
- Trial name
- NCT00519467
- Testing
- Chlorproguanil-dapsone-artesunate (CDA)
- Where
- 2 sites in Malawi, The Gambia
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Malaria,Falciparum
A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria
There is a need for paediatric formulations that permit accurate dosing and enhance patient compliance. However, for the treatment of malaria, scarce paediatric-friendly formulations are available on the market.
- Trial name
- NCT01992900
- Testing
- Eurartesim dispersible oral tablet, eurartesim film coated tablet
- Where
- 7 sites in Burkina Faso, Democratic Republic of the Congo and 3 more
- Volunteers
- 300 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Pneumococcal Vaccines
13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
This study will compare the immune responses of the infants who have been given 13vPnC in the mutidose vial formulation to the immune reponses of the infants who have been given 13vPnC in the single-dose syringe formulation.
- Trial name
- NCT01964716
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 2 sites in The Gambia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Pfizer